Summary

Judd Arnold has moved from “too cute by half” valuation work toward liquid inflections where he can start small, wait for proof, and then size aggressively. A former colleague found that only one in four or five high-conviction ideas actually worked, inspiring “junior varsity positions” that become large when the thesis begins playing out. Liquidity preserves the ability to change course.
The new screen is not merely cheapness but whether “people will care” once the story inflects. Arnold contrasts perpetually inexpensive, illiquid names with Nebius ($NBIS), which traded roughly 1–2 million shares out of the gate; Walker expected it to become highly liquid, potentially trading 25 million shares a day. Walker also cited $ASTS, T1 Energy ($TE), and WGS as examples of liquid, attention-driven inflections.
Traditional valuation can become secondary when a company-specific catalyst and a sector-wide re-rating arrive together. Arnold’s rough decomposition is 40% market, 30% sector, and 30% company; power demonstrated the payoff when names that had spent a decade at 15–20% free-cash-flow yields attracted generalist capital and re-rated dramatically. The lesson from Talen Energy ($TLN): trailing financials may miss an emerging scarcity story.
Arnold’s $TOI thesis is that capitated oncology can remove the fee-for-service incentive to prescribe the most expensive clinically acceptable drug. TOI offers Medicare Advantage plans a fixed per-member payment, then seeks equivalent outcomes with lower-cost drug regimens and outpatient care. Florida contracts can generate roughly $35 PMPM versus about $3 in California, while the oncology costs TOI touches are approximately $30–50 of a plan’s $1,000–$1,500 monthly premium.
TOI’s scaling advantage depends on controlling clinician behavior without owning every clinic. Thin markets such as Las Vegas leave an MSO with little leverage over oncologists; Florida combines enough patients, physicians, and hospitals for TOI to envision a network that is only 20% owned clinics and 80% MSO. Walker used Evolent Health as the cautionary example, saying it lacked enough control over the network and clinician behavior.
Walker’s central objection is that TOI resembles the failed value-based-care pitches behind Cano Health, VillageMD, Oak Street, and One Medical—and that CMS or insurers could eventually take back the economics. Arnold argues there is no MLR risk in this model because drug costs dominate and hospitals depend heavily on oncology-dispensing profit. He nevertheless acknowledges TOI’s disastrous post-SPAC land grab, when SG&A rose from roughly $40 million to $120 million before the patients arrived.
The TOI underwriting is explicitly an execution bet with unusually large operating leverage. Arnold disclosed ownership of roughly 2–4% of the company and estimated $20–40 million of EBITDA next year, building toward a $75 million 2027 exit rate; with about 130 million shares and $40 million of net debt, his two-year target is $15–30 versus roughly $4–$4.20 during the discussion. A drug-distributor-backed or private-equity buyer is his likely exit scenario.
Sizing is a cube, not a conviction score: expected price range, position size at each price, and discontinuous downside all matter. Liquidity cannot protect against a halt, fraud, or adverse regulatory gap, so Sable Offshore’s possible 25–40% overnight loss must constrain sizing even when the upside is $100. The same time-path logic explains both the Akorn merger-arbitrage squeeze and Warner Bros. trading below a hostile cash bid: “You miss the first 20, you miss the last 20, you capture the middle 60.”

Deep dive

1. Freedom from the pitch machine changed Arnold’s research process

Arnold left hedge funds at the start of 2020 and spent almost five years consulting. The recurring frustration was familiar from his analyst career: pitching a boss or client rewards a supposedly unique insight, which pushed him toward ideas that were “too cute by half” or unnecessarily illiquid.
Walker contrasted those complex situations with the simple financial-engineering stories he once preferred: a 2% top-line grower at 10 times free cash flow using cash for buybacks, or a levered buyback story. He said he did not think those had worked over the prior decade, while the hairier alternative might involve a deranged SPAC, a forced seller, several failing divisions, and one potentially valuable business.
Arnold’s institutional base rate was sobering: perhaps 10–20% odds that a PM cared about a pitch and less than 5% that a position actually entered the book. With approximately 10 consulting clients, at least one or two would usually engage, making the transmission problem visible in real time.
A former colleague supplied the portfolio implication after reviewing three years of results: only one in four or five high-conviction ideas worked. His proposed remedy—hold “junior varsity positions” and ramp when evidence arrives—became Arnold’s model of high-conviction inflection investing.
Substack lets Arnold write simply because “this is interesting,” while keeping investing intellectually personal and flexible. Arnold values being able to move on when a client dislikes a name; Walker separately described wanting the veto of “you don’t like it? Great,” and Arnold cited selling his entire publicly discussed Sable Offshore position in the $20s before recently returning to it.

2. Liquidity and “people will care” now outrank obvious cheapness

Arnold is deliberately exchanging some “valuation obviousness” for liquidity. MiX Telematics, which became Powerfleet and then $AIOT, could screen at seven or eight times EVA against theoretical 20-times value, yet never achieved the liquidity that would let the thesis compound through broader sponsorship.
The discussion of Nebius began around $18, with Arnold seeing a chance to lean in near $20 after venture investors entered. Walker said he was “100% certain that people will care”; the stock traded roughly 1–2 million shares out of the gate, and Walker expected it to become highly liquid, like a QQQ, potentially trading 25 million shares a day.
Walker’s $ASTS recollection was even less tethered to conventional precision: after the first contract sent the stock to $5, it returned to $4 while warrants traded near $1. “I don’t know; I just know it’s going 50 or 100,” he remembers thinking, because attention and liquidity were already evident.
Walker also cited T1 Energy ($TE), formerly FREYR, as a liquid former SPAC with a solar story, and WGS, an exome-and-genome company he said rose from around $2 to roughly $140. TOI is less obvious, but a 20% healthcare-services grower with fixed capital structure and a five-to-ten-year market can still command attention if execution appears.

3. Sector inflections can overwhelm the old valuation regime

Arnold is “less tethered to traditional valuation metrics” but more tethered to story, liquidity, and right-tail potential. At a $15–20 billion fund, an investor must actually be correct; at $500 million to $1 billion, sufficient liquidity can allow monetization without being “intellectually perfectly correct on a 20-year basis.”
His old framework assigned roughly 40% of an average stock’s return to the market, 30% to sector, and 30% to company. Calling the sector is therefore almost as valuable as finding company-specific alpha, with the best outcomes occurring when both inflect together.
Power was Arnold’s humbling example. Years of distress experience taught him that generators “go bankrupt every seven years,” so he dismissed Talen despite knowing its plant; then data-center demand brought generalists into a sector long priced at 15–20% free-cash-flow yields, while CEG eventually reached roughly 35 times earnings.
TOI is closer to “a company unto itself.” Arnold sees its economics as short-term market-insensitive and estimates that, over two years, perhaps 90% of the idiosyncratic move would be the stock itself—making it more sizeable than a commodity producer, cyclical retailer, or GDP-sensitive consumer name.

4. TOI monetizes a cheaper way to deliver oncology care

TOI buys cancer drugs, dispenses them through clinics, and provides infusion and related oncology services. Arnold estimates roughly half of patients receive care through hospitals—the highest-cost channel—while about 95% of the ecosystem still operates under fee-for-service incentives.
The large drug distributors can procure around ASP minus 20%, while the fee-for-service benchmark is ASP plus 6%, creating attractive spreads and allowing outpatient delivery to undercut hospitals. Their economic incentive nevertheless remains volume: six percent on a $20,000 therapy is much more valuable than six percent on a $2,000 alternative.
TOI goes “one level further.” It reviews the available therapies and, where it believes patient outcomes are equivalent, chooses the cheaper regimen; it then offers Medicare Advantage plans a capitated price rather than maximizing reimbursable drug volume.
Arnold framed the addressable economics as a $1,000–$1,500 monthly Medicare Advantage premium, of which oncology costs touched by TOI represent around $30–50 PMPM. TOI can propose taking the whole network’s risk near $30 PMPM while claiming roughly $20 PMPM of savings versus the existing benchmark.

5. Clinical control and local density determine whether TOI can scale

Hospitals complicate reform because oncology-dispensing income may represent 25–30% of hospital margin despite hospitals being only 2–3% margin businesses. Arnold argues CMS can attack dubious durable-medical-equipment or skin-graft spending more readily than oncology: “They don’t want to kill people,” and destabilizing hospital economics carries systemic consequences.
The operational barrier is not merely knowing which drugs cost less; TOI needs oncologists to follow its protocols. Walker used Evolent Health as the failure mode: he said the value-based provider lacked enough control over its network and clinician behavior, its MLR blew out, and its stock fell from approximately $35 to $4 over two years.
Las Vegas is too concentrated for the model to exert leverage: with perhaps 50 relevant oncologists, a physician challenged on expensive prescribing can ask where else the network will go. Florida offers dense populations of patients, hospitals, and oncologists, giving TOI more leverage over oncologists who will not cooperate.
That density creates the scaling unlock. Rather than hiring every oncologist—a six-to-nine-month process—TOI believes Florida, Texas, Ohio, and possibly North Carolina can support a structure of roughly 20% owned clinics and 80% MSO relationships; Florida PMPM economics are about $35 versus $3 in heavily delegated California.

6. The turnaround is real, but failed value-based care shadows it

TOI’s original post-SPAC strategy was a national land grab. SG&A expanded from approximately $40 million to $120 million in two years, capacity arrived before patients, and “they just lit money on fire”; a new CEO arrived about 2.5 years ago when Arnold says the business looked capable of going under.
The recent pivot pairs Florida clinic capacity with capitated contracts. Fee-for-service demand initially filled the clinics while those contracts were pending; TOI’s reported gross margin was around 15–17%, while Arnold says the capitated business carries 15–20% margins. As capacity shifts toward capitation on both drugs and patient services, he expects roughly 20% incremental margins and said Q4 EBITDA breakeven was in reach.
Walker’s pushback—worth keeping—is that Cano Health, VillageMD, Oak Street, and One Medical all sold variations of lower-cost outpatient value-based care before investors suffered. Arnold’s distinction is no MLR risk from the drug-driven model, plus staffing savings as TOI moves from roughly four oncologists per nurse practitioner toward one-to-one.
The transcript gives conflicting revenue-multiple figures: Arnold first said TOI was under one times revenue, then later said it was trading at seven times revenue. The other estimates remain explicit: approximately 130 million shares, $40 million of net debt, $20–40 million of next-year EBITDA, and a possible $75 million 2027 exit rate. Arnold’s two-year target is $15–30; he would reassess nearer two times revenue and views private equity as a likely buyer.

7. Reimbursement risk could create upside as well as compression

Walker asked the standard managed-care question: even if TOI saves money, why could CMS or insurers not simply reduce its fixed rate and demand that it “take it” or “go pound sand”? Arnold’s answer is that TOI sits on the side of lowering oncology costs rather than exploiting an isolated reimbursement loophole.
Arnold’s site visit reinforced that view. TOI’s lead Florida oncologist, formerly at ChenMed, described this as “the way it’s supposed to go”—although Walker’s concern remains that health plans could eventually retain more of the savings.
Arnold said he thinks Keytruda comes off patent in 2028, but TOI’s medical leaders rejected an immediate one-for-one switch to biosimilars. They expect physician behavior and fee-for-service incentives to delay convergence for four or five years.
That lag could itself become a profit pool: TOI might use lower-cost Keytruda alternatives while reimbursement benchmarks remain elevated. Arnold floated the possibility that the spread could generate 20–30% of company profits, while explicitly presenting it as a hypothetical rather than current earnings.

8. Sizing is a three-dimensional problem, not a conviction score

Arnold’s first defense against confirmation bias is a liquid portfolio and willingness to eject. Walker correctly challenged the slogan: a liquid stock can still be halted overnight in a fraud scenario, reopening near zero before even the fastest trader gets a vote.
Arnold narrowed his point to names without clear fraud risk, while acknowledging that fraud, earnings discontinuities, regulatory decisions, and “jump-to-default” scenarios cannot be solved with normal liquidity; they must reduce initial size. Sable, for example, could gap down 25–40% on action by California authorities even if its upside case remained much larger.
Position size therefore follows confidence in the downside boundary, not enthusiasm alone. Arnold asks whether the company is inside his circle of competence, whether he might have missed something, and whether the loss is bounded; after studying TOI over several years and building conviction, he felt able to make it a major position.
His geometric framing is a cube: the stock’s possible path from $10 to $20, how much is owned at $10, $11, and each subsequent price, plus the downside “below the iceberg.” The ideal is not buying the precise bottom but capturing the middle 60% with meaningful size.

9. Duration explains Sable, Akorn, and Netflix’s merger purgatory

Sable warrants near $1 before the SPAC closed offered years of duration against a perceived $100 upside case. In 2024, even a failed restart seemed two or three years away, so the downside was protected by time and volatility; by late summer 2025, regulatory setbacks and absent fire-marshal progress had compressed that protection.
Nebius offered the opposite balance sheet but similar option logic: roughly $18 per share against around $15 of cash plus several uncertain assets and an AI-data-center buildout. Walker viewed its team as “execution Jedis,” highlighted its relationship with Nvidia, and initially thought perhaps $75—then admitted, “How wrong I was,” about the scale of the outcome.
The Fresenius–Akorn broken merger showed how time itself can create a trade. With a $32–$33 cash deal, Akorn rose from roughly $11–$12 to $18 before trial as traders argued it “couldn’t die before the trial”; Fresenius then won its material-adverse-change case, and Akorn ultimately went bankrupt.
Warner Bros. produced similarly strange path-dependent pricing: Arnold said he had never seen a company receive a hostile cash offer near $30 and trade around $27 during a bidding war. He sees Netflix’s proposed acquisition creating up to two or three years of “merger purgatory,” notwithstanding seemingly conservative $2 billion synergy guidance.
Arnold’s concern is the lasting signal: Netflix historically bought almost nothing, so investors may keep asking what weakness made it pursue one of the largest acquisitions imaginable. Walker’s preferred outcome for Netflix is Paramount raising to $34 without a counterbid; completing on existing terms ranks second, while raising and adding substantial debt is worst.

Artificial Analysis: The Independent LLM Analysis House — with George Cameron and Micah Hill-Smith NVIDIA’s Jensen Huang on Reasoning Models, Robotics, and Refuting the “AI Bubble” Narrative